Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**C5-PE38** is an ambiguous preclinical recombinant nanobody-PE38 immunotoxin construct name that has been independently used for at least two distinct molecules. One construct combines a canine B-cell-lymphoma-selective C5 single-domain antibody with the truncated *Pseudomonas aeruginosa* exotoxin A payload PE38 and showed cytotoxicity and tumor-growth inhibition in canine B-cell lymphoma models. A separate construct uses a C5 nanobody directed against cell-surface glucose-regulated protein 78 and was evaluated in colorectal cancer and melanoma models, where it induced endoplasmic-reticulum stress, apoptosis, immunogenic cell death, and STING-associated antitumor immune activation. These constructs should not be treated as one molecular asset merely because they share the same published construct name. ([frontiersin.org](https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1491934/full))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C5-PE38.